Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAF mutated, microsatellite-stable colon cancer: A case report and literature review.

Metastatic BRAF mutated colorectal cancer is associated with poor overall survival and modest effectiveness to standard therapies. Furthermore, survival is influenced by the microsatellite status. Patients with microsatellite-stable and BRAF mutated colorectal cancer have the worst prognosis under the wide range of genetic subgroups in colorectal cancer.

REGO-ACT: assessment of physical activity during treatment with regorafenib for metastatic colorectal cancer.

Background: A frequent side effect of the multikinase inhibitor regorafenib is fatigue. Physical activity has shown potential in reducing cancer-related fatigue.

Methods: This non-interventional pilot study assessed physical activity levels of metastatic colorectal cancer (mCRC) patients treated with regorafenib based on median daily step counts measured at 1‑week intervals using a pedometer.

Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.

Background/aim: Although high response rates using the doublet-chemotherapy of oxaliplatin and irinotecan as well as its combination with cetuximab in advanced gastric cancer were shown in previous trials, time to progression was short, suggesting acquired chemotherapy resistance.

Patients And Methods: Sequential chemotherapy (oxaliplatin and irinotecan followed by docetaxel) combined with bevacizumab was investigated in the GASTRIC-3 trial. Patients achieving at least stable disease were continued on maintenance bevacizumab.

Complications associated with the use of Port-a-Caths in patients with malignant or haematological disease: a single-centre prospective analysis.

Totally implantable central venous catheters are widely used in the management of patients with haematological or malignant disease. This paper investigates device-related complications and compares it with the literature. A total of 143 Port-a-Caths (PaCs) were implanted in 140 patients at a single centre during 2004 and followed until March 2005.